Patents by Inventor Felix Kratz

Felix Kratz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230391794
    Abstract: The present subject matter provides for albumin-binding prodrugs, maytansinoid-based compounds, and uses thereof.
    Type: Application
    Filed: December 21, 2022
    Publication date: December 7, 2023
    Inventors: Felix Kratz, Khalid Abu Ajaj, Anna Warnecke, Friederike I. Nollmann, Stephan David Koester, Javier Garcia Fernandez, Lara Pes, Heidi-Kristin Walter, Johannes Pall Magnusson, Serghei Chercheja, Patricia Perez Galan, Federico Medda, Steffen Josef Daum
  • Patent number: 11572373
    Abstract: The present subject matter provides for albumin-binding prodrugs, maytansinoid-based compounds, and uses thereof.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: February 7, 2023
    Assignee: LADRX CORPORATION
    Inventors: Felix Kratz, Khalid Abu Ajaj, Anna Warnecke, Friederike I. Nollmann, Stephan David Koester, Javier Garcia Fernandez, Lara Pes, Heidi-Kristin Walter, Johannes Pall Magnusson, Serghei Chercheja, Patricia Perez Galan, Federico Medda, Steffen Josef Daum
  • Publication number: 20230023537
    Abstract: The present invention provides a compound having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof, for the controlled delivery and release of Agent.
    Type: Application
    Filed: June 3, 2022
    Publication date: January 26, 2023
    Inventors: Felix Kratz, Khalid Abu Ajaj, André Warnecke, Stephan David Koester, Friederike I. Nollmann, Simon Waltzer, Olga Fuchs, Javier García Fernandez
  • Patent number: 11384104
    Abstract: The present invention provides a compound having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof, for the controlled delivery and release of Agent.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: July 12, 2022
    Assignee: CENTURION BIOPHARMA CORPORATION
    Inventors: Felix Kratz, Khalid Abu Ajaj, André Warnecke, Stephan David Koester, Friederike I. Nollmann, Simon Waltzer, Olga Fuchs, Javier García Fernandez
  • Patent number: 11377473
    Abstract: The present disclosure provides for albumin-binding prodrugs of auristatin E derivatives and uses thereof.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: July 5, 2022
    Assignee: CENTURION BIOPHARMA CORPORATION
    Inventors: Felix Kratz, Khalid Abu Ajaj, Anna Warnecke, Friederike I. Nollmann, Stephan David Koester, Javier Garcia Fernandez, Lara Pes, Heidi-Kristin Walter, Johannes Pall Magnusson, Serghei Chercheja, Patricia Perez Galan, Federico Medda, Steffen Josef Daum
  • Publication number: 20210353783
    Abstract: The present disclosure provides albumin-binding radioactive metal complexes and uses thereof, including diagnosing and treating disease.
    Type: Application
    Filed: July 16, 2019
    Publication date: November 18, 2021
    Inventors: Felix Kratz, Khalid Abu Ajaj, Anna Warnecke, Friederike I. Nollmann, Stephan David Koester, Javier Garcia Fernandez, Lara Pes, Steffen Daum, Johannes Pall Magnusson, Serghei Chercheja, Patricia Perez Galan, Federico Medda
  • Publication number: 20200385421
    Abstract: The present disclosure provides for albumin-binding prodrugs of auristatin E derivatives and uses thereof.
    Type: Application
    Filed: November 30, 2018
    Publication date: December 10, 2020
    Inventors: Felix Kratz, Khalid Abu Ajaj, Anna Warnecke, Friederike I. Nollmann, Stephan David Koester, Javier Garcia Fernandez, Lara Pes, Heidi-Kristin Walter, Johannes Pall Magnusson, Serghei Chercheja, Patricia Perez Galan, Federico Medda, Steffen Josef Daum
  • Publication number: 20200385403
    Abstract: The present subject matter provides for albumin-binding prodrugs, maytansinoid-based compounds, and uses thereof.
    Type: Application
    Filed: November 30, 2018
    Publication date: December 10, 2020
    Inventors: Felix Kratz, Khalid Abu Ajaj, Anna Warnecke, Friederike I. Nollmann, Stephan David Koester, Javier Garcia Fernandez, Lara Pes, Heidi-Kristin Walter, Johannes Pall Magnusson, Serghei Chercheja, Patricia Perez Galan, Federico Medda, Steffen Josef Daum
  • Patent number: 10426841
    Abstract: The present invention relates to a composition and a combination comprising at least one first drug and at least one protein-binding prodrug, wherein the protein-binding prodrug comprises a protein-binding group, a second drug, and a linker that can be cleaved hydrolytically, enzymatically, or in a pH-dependent manner in the body, as well as to a kit and a pharmaceutical composition comprising said composition or combination.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: October 1, 2019
    Assignee: Vergell Medical S.A.
    Inventor: Felix Kratz
  • Patent number: 10220101
    Abstract: The present invention relates to a composition and a combination comprising at least one first drug and at least one protein-binding prodrug, wherein the proteinbinding prodrug comprises a protein-binding group, a second drug, and a linker that can be cleaved hydrolytically, enzymatically, or in a pH-dependent manner in the body, as well as to a kit and a pharmaceutical composition comprising said composition or combination.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: March 5, 2019
    Assignee: Vergell Medical S.A.
    Inventor: Felix Kratz
  • Publication number: 20190002484
    Abstract: The present invention provides a compound having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof, for the controlled delivery and release of Agent.
    Type: Application
    Filed: June 17, 2016
    Publication date: January 3, 2019
    Inventors: Felix Kratz, Khalid Abu Ajaj, André Warnecke, Stephan David Koester, Friederike I. Nollmann, Simon Waltzer, Olga Fuchs, Javier García Fernandez
  • Patent number: 9901644
    Abstract: A prodrug is provided which includes at least two different pharmaceutically and/or diagnostically active compounds independently bound by cleavable linkers and a protein-binding moiety which is capable of binding to carrier a molecule.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: February 27, 2018
    Assignee: KTB Tumorforschungsgesellschaft mbH
    Inventors: Felix Kratz, Irmgard Merfort
  • Publication number: 20180028679
    Abstract: The present invention relates to a composition comprising at least two different albumin-based drug delivery systems, as well as to a pharmaceutical composition comprising said composition.
    Type: Application
    Filed: September 25, 2017
    Publication date: February 1, 2018
    Inventors: Felix Kratz, Andre Warnecke
  • Publication number: 20170319707
    Abstract: The present invention relates to a composition and a combination comprising at least one first drug and at least one protein-binding prodrug, wherein the protein-binding prodrug comprises a protein-binding group, a second drug, and a linker that can be cleaved hydrolytically, enzymatically, or in a pH-dependent manner in the body, as well as to a kit and a pharmaceutical composition comprising said composition or combination.
    Type: Application
    Filed: July 14, 2017
    Publication date: November 9, 2017
    Inventor: Felix KRATZ
  • Patent number: 9801949
    Abstract: The present invention relates to a composition comprising at least two different albumin-based drug delivery systems, as well as to a pharmaceutical composition comprising said composition.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: October 31, 2017
    Assignee: KTB TUMORFORSCHUNGSGESELLSCHAFT MBH
    Inventors: Felix Kratz, Andre Warnecke
  • Publication number: 20160346396
    Abstract: The present invention relates to a prodrug which comprises at least two different pharmaceutically and/or diagnostically active compounds independently bound by cleavable linkers and a protein-binding moiety which is capable of binding to carrier a molecule.
    Type: Application
    Filed: August 15, 2016
    Publication date: December 1, 2016
    Inventors: Felix KRATZ, Irmgard MERFORT
  • Patent number: 9446138
    Abstract: A prodrug is provided which includes at least two different pharmaceutically and/or diagnostically active compounds independently bound by cleavable linkers and a protein-binding moiety which is capable of binding to carrier a molecule.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: September 20, 2016
    Assignee: KTB TUMORFORSCHUNGSGESELLSCHAFT MBH
    Inventors: Felix Kratz, Irmgard Merfort
  • Patent number: 9320803
    Abstract: The present invention relates to a prodrug, comprising a pharmaceutically and/or diagnostically active compound, and one or more bisphosphonate groups, to a process for producing such a prodrug, and to a pharmaceutical composition comprising said prodrug, to be used for the treatment of bone-related disorders such as bone cancer.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: April 26, 2016
    Assignee: KTB Tumorforschungsgesellschaft MBH
    Inventors: Felix Kratz, Katrin Hochdoerffer
  • Patent number: 9216228
    Abstract: The present invention relates to a prodrug which comprises at least one pharmaceutically and/or diagnostically active compound bound by a cleavable linker, a receptor and/or antigen targeting moiety and a protein-binding moiety which is capable of binding to a carrier molecule.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: December 22, 2015
    Assignee: KTB Tumorforschungsgesellschaft MBM
    Inventor: Felix Kratz
  • Publication number: 20150196573
    Abstract: The invention relates to a method for producing injectable medicament preparations containing a therapeutically and/or diagnostically effective substance which is comprised of an active agent, of a spacer molecule and of at least one protein-binding molecule. After being brought into contact with the body, said therapeutically and/or diagnostically effective substance covalently bonds to the body fluid constituents or tissue constituents via the protein-binding molecule, thus providing a form of transport of the active agent that an be hydrolytically or enzymatically cleaved, according to pH, in the body while releasing the active agent.
    Type: Application
    Filed: August 26, 2014
    Publication date: July 16, 2015
    Inventor: Felix Kratz